Lead Product(s): GtCCR4
Therapeutic Area: Ophthalmology
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Mitsubishi UFJ Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 13, 2020
In a project under TaNeDS, Nagoya Institute of Technology discovered that a highly active, novel photoresponsive protein2 could be applied to the restoration of vision.